english.prescrire.org > Prescrire International > N°209 - November 2019

n°209

November 2019

Issue Contents
Editorial

Free  Mediator°... now what?

p.255

New Products


Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection

p.257-259
Risk of resistance to rilpivirine must be taken into account

Bictegravir + emtricitabine + tenofovir alafenamide (Biktarvy°) in HIV infection

p.259

Cariprazine (Reagila°) and schizophrenia

p.259

Olaparib (Lynparza°) in ovarian cancer without a BRCA mutation

p.260-262
Excessive adverse effects for women in remission

Follitropin delta (Rekovelle°): dosage in micrograms

p.262

INN Common stem: -parib

p.262

Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia

p.263-264
Uncertain effect on survival and serious adverse effects

Inset. Vacillation over marketing authorisation

p.264

Adverse Effects


Fenspiride: serious adverse effects that took a very long time to be taken into account

p.265-267

Tranexamic acid: deaths from thrombo­sis

p.267

Free  Gliptins: joint pain and exposure to NSAIDs

p.268

Low-dose aspirin + NSAIDs: reduced antiplatelet effect

p.269

Reviews


Queries and Comments. 9-valent papillomavirus vaccine: an overlooked advance?

p.270-272

Severe community-acquired pneumonia

p.272-273
Fewer deaths with a combination of antibiotic + cortico­steroid

Diabetes and primary prevention of cardiovascular disease

p.273
As many harms as benefits with aspirin

Action to take when confronted with probable acute coronary syndrome

p.274
While awaiting the arrival of the emergency medical services

Outlook


Faces of Mediator

p.268

Industrial protectionism and drugs: too many negative effects

p.275-277

Inset. Pharmaceutical industrial property, in brief

p.277

Free  Servier and French drug regulatory agency on trial

p.278-279

Diseases still being neglected

p.279

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe